Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 7/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15593981 | 0.85 | CYP17A1 (0.50) | CYP2A6CYP3A4CYP2E1CYP2D6CYP2C9 | |
| SCHEMBL13545698 | 0.82 | CYP2A6 (0.53) | CYP2A6CYP3A4CYP2E1CYP2D6CYP2C9 | |
| SCHEMBL7673706 | 0.81 | PARP10 (0.46) | CYP2A6CYP3A4CYP2E1CYP2D6CYP2C9 | |
| SCHEMBL17991851 | 0.79 | PARP10 (0.42) | PARP10PARP11AKR1C3AKR1C2LMNA | |
| SCHEMBL10263187 | 0.79 | ESR2 (0.44) | CYP2A6CYP2C9CYP2B6CYP2C19PARP10 | |
| SCHEMBL18378751 | 0.78 | CYP2A6 (0.56) | CYP2A6CYP3A4CYP2E1CYP2D6CYP2C9 | |
| SCHEMBL16806032 | 0.77 | TDO2 (0.54) | CYP2A6CYP3A4CYP2E1CYP2D6CYP2C9 | |
| SCHEMBL10094646 | 0.77 | TDO2 (0.54) | CYP2A6CYP3A4CYP2E1CYP2D6CYP2C9 | |
| SCHEMBL22351934 | 0.77 | CYP2A6 (0.51) | CYP2A6CYP3A4CYP2E1CYP2D6CYP2C9 | |
| SCHEMBL2665899 | 0.77 | CYP2A6 (0.47) | CYP2A6CYP3A4CYP2E1CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040966-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-06-22 | — | — | US | disclosed |
| WO-2020099511-A1 | BENZIMIDAZOLE-2-METHYL-MORPHOLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020007964-A1 | 2-(2-AZABICYCLO[3.1.0]HEXAN-1-YL)-1H-BENZIMIDAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-01-09 | — | — | WO | disclosed |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-08-29 | — | — | US | disclosed |
| US-10329287-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-25 | — | — | US | disclosed |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-10-26 | — | — | US | disclosed |
| US-9732075-B2 | Benzimidazole-proline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-15 | — | — | US | disclosed |
| EP-2855453-B1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | disclosed |
| US-20160340360-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-9409908-B2 | Dihydropyridone p1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166527-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | CYP2A6 1296/4885CYP3A4 1012/4885CYP2E1 1046/4885 |
| US-10329287-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | CYP2A6 1286/4885CYP3A4 1106/4885CYP2E1 1138/4885 |
| US-11040966-B2 | Benzimidazole-proline derivatives | HCRTR1, HCRTR2, NPY1R | CYP2A6 1286/4885CYP3A4 1106/4885CYP2E1 1138/4885 |
| US-20190263797-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | CYP2A6 1286/4885CYP3A4 1106/4885CYP2E1 1138/4885 |
| US-20160340360-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | CYP2A6 1315/4885CYP3A4 419/4885CYP2E1 1376/4885 |
| US-20170305897-A1 | BENZIMIDAZOLE-PROLINE DERIVATIVES | HCRTR1, HCRTR2, NPY1R | CYP2A6 1286/4885CYP3A4 1106/4885CYP2E1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.